Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Prostatic Neoplasms 1106Carcinoma, Renal Cell 412Urinary Bladder Neoplasms 280Kidney Neoplasms 177Neoplasm Metastasis 134Neoplasms 132Carcinoma, Non-Small-Cell Lung 109Carcinoma, Transitional Cell 108Breast Neoplasms 94Melanoma 90Ovarian Neoplasms 70Lung Neoplasms 67Colorectal Neoplasms 58Pancreatic Neoplasms 49Sarcoma 48Wilms Tumor 41Uterine Cervical Neoplasms 37Head and Neck Neoplasms 37Stomach Neoplasms 36Testicular Neoplasms 33Non-Muscle Invasive Bladder Neoplasms 33Esophageal Neoplasms 33Squamous Cell Carcinoma of Head and Neck 31Neuroblastoma 30Lymphoma, Non-Hodgkin 29Colonic Neoplasms 28Small Cell Lung Carcinoma 27Carcinoma, Hepatocellular 27Urethral Neoplasms 25Triple Negative Breast Neoplasms 23

Interventions

mirabegron 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urinary Bladder Neck Obstruction × Genitourinary × Clear all
NCT00410514 2014-04-04

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Astellas Pharma Inc

Phase 2 Completed
200 enrolled 24 charts
EndocrineGenitourinary

Urinary Bladder Neck Obstruction, Multiple Endocrine Neoplasia Type 1, Lower Urinary Tract Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡